ETFs Exelixis, Inc.

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2026 am IST			5-day change	1st Jan Change
55.55 ^USD	-0.39%		-1.00%	+26.74%

13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT

ETFs positioned on Exelixis, Inc.

Name		YTD change	Weight	AuM
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED		0.00%	1.59%	2 M€

1 2

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Employees

1,077

Sector

Biotechnology & Medical Research

More about the company